The Spanish pharmaceutical industry seeks greater strategic autonomy in health
The Secretary of State for Health, Cruz Cigudosa, has recently highlighted the importance of strengthening the pharmaceutical sector in Spain. The main objective is to build a stronger, more innovative, and competitive industry that allows the country to gain independence in the supply of essential medicines and medical products.
During her speech, Cigudosa stressed that strategic autonomy in the field of health is a priority for the Government. In a global context where supply chains can suffer interruptions, having domestic production capacity is considered fundamental to ensuring the safety of Spanish patients.
To achieve this purpose, the Executive is committed to fostering research and development (R&D) within our borders. Collaboration between pharmaceutical companies, research centers, and the public health system is seen as the key to driving innovation and attracting new investment to the sector.
Furthermore, the aim is to improve the competitiveness of national companies in the European market. By strengthening the local industry, Spain not only secures access to vital treatments but also boosts the creation of skilled jobs and economic growth in the biotechnology sector.
In conclusion, strengthening the Spanish pharmaceutical industry is a key strategy for ensuring the well-being of the population. Authorities continue to work on policies that will allow for a reduction in foreign dependency and consolidate Spain as a European benchmark in the production and development of healthcare solutions.